期刊
CANCER IMMUNOLOGY RESEARCH
卷 10, 期 5, 页码 545-557出版社
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/2326-6066.CIR-21-1105
关键词
-
资金
- University of Sevilla (Spain)
- US DoD BRCP [BC180476P1]
- 2019 Laura Ziskin Prize in Translational Research from the Stand Up to Cancer (SU2C) [ZP-6177]
- Mantle Cell Lymphoma Research Initiative (MCL-RI) grant from the Leukemia and Lymphoma Society
- Dept. of Radiation Oncology at Weill Cornell Medicine (New York)
- Functional Genomics Initiative (New York)
- Lytix Biopharma (Oslo, Norway)
- Phosplatin (New York)
MDSCs, a group of cells with immunosuppressive functions, have been found to be associated with tumor progression and treatment resistance. They also affect the efficacy of radiotherapy, making them potential targets for immunotherapeutic tumor control.
Myeloid-derived suppressor cells (MDSC) are a heterogeneous population of pathologically activated, mostly immature, myeloid cells that exert robust immunosuppressive functions. MDSCs expand during oncogenesis and have been linked to accelerated disease progression and resistance to treatment in both preclinical tumor models and patients with cancer. Thus, MDSCs stand out as promising targets for the development of novel immunotherapeutic regimens with superior efficacy. Here, we summarize accumulating preclinical and clinical evidence indicating that MDSCs also hamper the efficacy of radiotherapy (RT), as we critically discuss the potential of MDSC-targeting strategies as tools to achieve superior immunotherapeutic tumor control by RT in the clinic.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据